Issues related to secondary osteoporosis associated with growth hormone deficiency in adulthood

Czech version

Authors: Martin Kužma ¹; Peter Jackuliak ¹; Zdenko Killinger ¹; Peter Vaňuga ²; Juraj Payer ¹
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava, Slovenská republika ¹; Národný endokrinologický a diabetologický ústav, Ľubochňa, Slovenská republika ²
Published in: Vnitř Lék 2017; 63(10): 658-661
Category: Reviews

Overview

Growth hormone (GH) increases linear bone growth through complex hormonal reactions, mainly mediated by insulin like growth factor 1 (IGF1) that is produced mostly by hepatocytes under influence of GH and stimulates differentiation of epiphyseal prechondrocytes. IGF1 and GH play a key role in the linear bone growth after birth and regulation of bone remodelation during the entire lifespan. It is known that adult GH deficient (GHD) patients have decreased BMD and increased risk of low-impact fractures. Most data gathered thus far on the effect of GH replacement on bone status comprise the measurement of quantitative changes of bone mass. Some animal studies with GHD showed that the bone microarchitecture, measured using computed tomography methods, is significantly compromised and improve after GH replacement. However, human studies did not show significantly decreased bone microarchitecture, but limited methodological quality does not allow firm conclusions on this subject.

Key words:
bone mass – bone quality – fracture – growth hormone – IGF1

Sources

1. Fauci AS, Braunwald E, Kasper DL et al (eds). Harrison‘s Principles of Internal Medicine. 17th ed. McGraw-Hill Professional 2008. ISBN 978–0071466332.

2. Rizzoli R, Bonjour JP. Determinants of peak bone mass and mechanisms of bone loss. Osteoporos Int 1999; 9(Suppl 2): S17-S23.

3. Ohlsson C, Bengtsson BA, Isaksson OG et al. Growth hormone and bone. Endocr Rev 1998; 19(1): 55–79.

4. Bouillon R. Growth hormone and bone. Horm Res 1991; 36(Suppl 1): 49–55.

5. Holmes SJ, Economou G, Whitehouse RW et al. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78(3): 669–674.

6. Conway GS, Szarras-Czapnik M, Racz K et al. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 2009; 160(6): 899–907. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-08–0436>.

7. Whitehead HM, Boreham C, McIlrath EM et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 1992; 36(1): 45–52.

8. Binnerts A, Swart GR, Wilson JH et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol (Oxf) 1992; 37(1): 79–87.

9. Johansson AG, Engström BE, Ljunghall S et al. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84(6): 2002–2007.

10. Välimäki MJ, Salmela PI, Salmi J et al. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 1999; 140(6): 545–554.

11. Wüster C, Slenczka E, Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: Is there a need for additional growth hormone substitution? Klin Wochenschr 1991; 69(16): 769–773.

12. Rosén T, Wilhelmsen L, Landin-Whilhelmsen K et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997; 137(3): 240–245.

13. Wüster C, Abs R, Bengtsson BÅ et al. on behalf of the KIMS study group the KIMS international board. The influence of growth hormone deficiency, growth hormone replacement therapy and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001; 16(2): 398–405.

14. Holmer H, Svensson J, Rylander L et al. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J Bone Miner Res 2007; 22(12): 1842–1850.

15. Brixen K, Nielsen HK, Mosekilde L et al. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 1990; 5(6): 609–618.

16. Johansson AG, Lindh E, Blum WF et al. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996; 81(1): 44–48.

17. Nielsen HK, Jørgensen JO, Brixen K et al. Serum osteocalcin and bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: dose-response studies with biosynthetic human GH. Calcif Tissue Int 1991; 48(2): 82–87.

18. Burman P, Johansson AG, Siegbahn A et al. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997; 82(2): 550–555.

19. Clanget C, Seck T, Hinke V et al. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf) 2001; 55(1): 93–99.

20. Elbornsson M, Gotherstrom G, Bosaeus I et al. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 2012; 166(5): 787–795. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-11–1072>.

21. Elbornsson M, Gotherstrom G, Franco C et al. Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency. Eur J Endocrinol 2012; 166(2): 181–189. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-11–0886>.

22. Kužma M, Kužmová Z, Zelinková Z et al. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res 2014; 24(1): 22–28. <http://dx.doi.org/10.1016/j.ghir.2013.12.001>.

23. Arwert LI, Deijen JB, Muller M et al. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm Behav 2005; 47(3): 343–349.

24. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7(2): 137–145.

25. Bravenboer N, Holzmann PJ, ter Maaten JC et al. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men. J Bone Miner Res 2005; 20(10): 1778–1784.

26. Kristensen E, Hallgrimsson B, Morck DW et al. Microarchitecture, but not bone mechanical properties, is rescued with growth hormone treatment in a mouse model of growth hormone deficiency. Int J Endocrinol 2012; 2012: 294965. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/294965>.

27. Kužma M, Binkley N, Bednárová A et al. Trabecular bone score change differs with regard to 25(OH)D levels in patients treated for adult-onset growth hormone deficiency. Endocr Pract 2016; 22(8): 951–958. Dostupné z DOI: <http://dx.doi.org/10.4158/EP151183.OR>.